Post-earnings recap
Reported
Tue, Apr 28, 2026
EPS actual
$1.81
EPS est.
$1.14
EPS surprise
+58.77%
1-day move
+2.12%
Incyte's strong EPS performance exceeded analysts' expectations, contributing to a 1.13% increase in stock price. The company did not disclose revenue figures, which leaves some uncertainty for investors. Management's positive tone suggests confidence in future performance, but the lack of guidance may lead to cautious sentiment among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.81 | $1.37 | +58.77% |
| Revenue | N/A | $1.2B | N/A |
Overall, management conveyed a positive outlook on earnings performance while acknowledging the lack of revenue guidance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They emphasized their commitment to ongoing research and development.
Incyte Corporation is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Operating in the Health Care sector, Incyte's work is crucial as it addresses unmet medical needs and aims to improve patient outcomes through its drug development efforts.
Last quarter
In the last quarter, Incyte reported an EPS of $1.80, exceeding expectations by nearly 10%. However, the stock price fell by over 8% the following day, indicating market concerns despite the positive earnings surprise.
EPS beat streak
5Q
EPS beat rate
88%
Avg EPS surprise
+24.12%
Avg 1-day reaction
+2.20%
Analysts are cautiously optimistic about Incyte's upcoming earnings, expecting a solid EPS of $1.37 and revenue of $1.2 billion. The market is closely watching for any signs of growth or challenges in their product pipeline.
Bull case
If Incyte can beat EPS estimates and show strong revenue growth, it could signal robust demand for its therapies, potentially driving the stock higher.
Bear case
Conversely, if the company misses earnings expectations or provides weak guidance, it may raise concerns about its future growth prospects, leading to a decline in stock price.
Key metrics to watch
EPS
$1.37Earnings per share is a key indicator of profitability and will show how well Incyte is managing its costs and generating income.
Revenue
$1.2BRevenue figures will provide insight into the company's sales performance and market demand for its products.
The print will turn on these.
Q1
Will Incyte's EPS exceed the consensus estimate of $1.37?
A beat on EPS could indicate strong operational performance and boost investor confidence in the company's growth trajectory.
Q2
What guidance will management provide regarding future revenue growth?
Guidance on revenue growth is crucial for understanding the company's outlook and could significantly impact market sentiment.
—
Est. EPS
$1.52
Est. Rev
$3.6B
Impl. Move
±39.2%
Why consensus could be wrong
The consensus may underestimate Incyte's ability to leverage its recent product developments, which could drive stronger than expected revenue growth.
Supporting evidence
Incyte has a history of beating EPS estimates, with a 63% beat rate over the last eight quarters.
The options market is pricing a larger move than the historical average, suggesting that traders expect significant news.
Insider selling may indicate a strategic shift rather than a lack of confidence in the company's future.
Key risk
If Incyte's revenue growth exceeds $1.3 billion, it could challenge the current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Incyte can maintain its growth momentum amidst competitive pressures and market conditions.
Bull confirmed if
An EPS of $1.50 or higher would confirm the bull case, indicating strong financial health.
Bear confirmed if
An EPS below $1.00 would confirm the bear case, raising concerns about profitability.
What the market is pricing for the move.
Implied Move
±7.36%
Historical Avg
±6.6%
The options market is pricing in a significant move of over 7% in either direction, indicating uncertainty about the earnings report.
Options are pricing ±2.8% while INCY has averaged ±6.6% over the last 8 prints — setup is pricing cheap.
ATM IV
0.5%
30d HV
24.9%
Cross-company pattern from 30 similar setups.
Prior-quarter beat + options rich in Health Care
Fade rate: 7 of 20 (35%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 20 (65%) held or extended their move within 5 days — this setup typically holds direction. The average absolute 1-day move is 5.8%, with a raw directional average of +2.2% (modestly positive historical bias).
Smart-money positioning from the most recent 13F filings.
Institutional
103.39%
of float
Insider
1.85%
of float
Holders
1,282
institutions
Top Holders· as of Jun 2026
Baker Bros. Advisors, LP
30,762,330 sh · $3.5B
15.18%
0.1%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Incyte beats expectations, history suggests the stock could rise by around 0.94% on the following day, confirming positive market sentiment.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors await further clarity from management's commentary.
Miss
A miss on earnings could lead to a decline of about 0.20%, reflecting disappointment and concerns over future performance.
The lines on the call that would change the story.
Blackrock Inc.
18,032,718 sh · $2.0B
8.90%
-5.0%
Dodge & Cox Inc.
11,957,326 sh · $1.4B
5.90%
-2.4%
Vanguard Capital Management LLC
11,024,289 sh · $1.3B
5.44%
0.9%
State Street Corporation
9,722,336 sh · $1.1B
4.80%
0.8%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.